Deal Spotlight
Aug 14, 2026August 14, 2026
Vivid Dx raises €13.2M Seed backed by Cedars-Sinai Intellectual Property Co, Jameel Investment Management Company, Oxford Sciences Enterprises
€13.2M
round size
seed
stage
The funding round closed on July 29, 2026, with participation from Cedars-Sinai Intellectual Property Co, Jameel Investment Management Company, and Oxford Sciences Enterprises. The company has no prior rounds and reported no total funds raised before this investment.
Vivid Dx develops a diagnostic platform for early cancer detection using liquid biopsy and circulating tumour DNA for non-invasive, accurate screening. The company is based in the United Kingdom and operates in Healthcare & Life Sciences.
Brouky tracks 269 deals in Healthcare & Life Sciences in the UK over the last 12 months with a median deal size of €11.2M.
Related insights
- Deal SpotlightSedipec raises EUR4M Seed backed by Starquest
- Deal SpotlightArmadin raises EUR235M Series B backed by 8VC, Accel, Andreessen Horowitz and others
- Startup ProfileNovastart creates an infinite canvas where people and AI agents collaborate in real time
- Deal SpotlightMoffett AI raises EUR130M in Series C+ backed by Biqiu Capital and others
Explore the full dataset
Brouky tracks 37,000+ investors and 122,000+ investments across 134,000+ startups. Search by country, stage, and sector.